# Investigation of PSMA PET/CT as an Imaging Biomarker in Solid Tumors

> **NCT03453528** · NA · COMPLETED · sponsor: **Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS** · enrollment: 1225 (actual)

## Conditions studied

- Prostate-specific Membrane Antigen
- mCRPC or Advanced/Metastatic Solid Tumors

## Interventions

- **DRUG:** 68Ga-PSMA

## Key facts

- **NCT ID:** NCT03453528
- **Lead sponsor:** Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-04
- **Primary completion:** 2024-12-04
- **Final completion:** 2025-01-03
- **Target enrollment:** 1225 (ACTUAL)
- **Last updated:** 2025-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03453528

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03453528, "Investigation of PSMA PET/CT as an Imaging Biomarker in Solid Tumors". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03453528. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*